*Concept image – In stealth-mode development
Simplified Microsampling
SOLVING a
GLOBAL PROBLEM
OF IMPRACTICAL
SAMPLING
STANDARDS!
through painless, self-sampling
of fluids from the skin.
through painless,
self-sampling of
fluids from the skin.
* Concept image – In stealth-mode development
* Concept image – In stealth-mode development
*Concept image – In stealth-mode development
Simplified Microsampling
Unlocking a
multi-billion
dollar
market within
bio-samplig!
– through painless, self-sampling of fluids from the skin.
– through painless,
self-sampling of
fluids from the skin.
*Concept image – In stealth-mode development
Simplified MicrosamplingSOLVING a
GLOBAL PROBLEM OF IMPRACTICAL
SAMPLING
STANDARDS!
– THROUGH PAINLESS,
SELF-SAMPLING OF FLUIDS FROM THE SKIN!
OUR MISSION
Providing the most cost-efficient and easy-to-use devices for reliable and scalable microsampling of body fluids from the skin at the point-of-care
A micro-solution to a macro-problem
We unlock a new era of biomarker detection and diagnostics, by simplifying access to bio-samples.
The Opportunity
A paradigm shift
Tremendous advancements in analytical techniques –
Now require less sample volume, facilitating easier collection.The recent technological advancements within biomolecular analysis have reduced the sample size needed for diagnostic detection while driving demand for more accessible bio-samples.
Our innovative microsampling technology arrives at the perfect time, offering a cost-effective and scalable solution for precision medicine monitoring, biomarker detection, and population screenings for early-onset prevention.
By simplifying sample collection, we empower researchers, clinicians, and public health initiatives to unlock new insights, enhance bio-information accessibility, and improve patient outcomes like never before.
The Opportunity
A paradigm shift
Tremendous advancements in analytical techniques –
Now require less sample volume, facilitating easier collection.The recent technological advancements within biomolecular analysis have reduced the sample size needed for diagnostic detection while driving demand for more accessible bio-information.
Our innovative microsampling technology arrives at the perfect time, offering a cost-effective and scalable solution for precision medicine monitoring, biomarker detection, and population screenings for early-onset prevention.
By simplifying sample collection, we empower researchers, clinicians, and public health initiatives to unlock new insights, enhance bio-information accessibility, and improve patient outcomes like never before.
The Problem
Impractical Sampling StandardsThe accessibility to critical health data is negatively impacted by outdated and complex sampling standards. Access to diagnostic information is a fundament of modern healthcare. Yet, traditional blood sampling methods – such as venipuncture – are invasive, costly, and reliant on trained professionals and complex logistics, including biohazard handling and cold-chains.
These challenges make routine testing and large-scale health monitoring highly impractical, particularly in remote, underserved, or resource-limited regions.
An estimated 1/3 of the global population suffer from one or more preventable chronic diseases, underscoring the urgent need for more effective disease management.
Additionally, emerging fields like precision medicine and bioinformatics-driven health insights require scalable and reliable sampling solutions to unlock their full potential. This also affects clinical trials, where 80% are delayed due to difficulty in participant recruitment and low compliance.
Addressing these limitations is critical and requires a shift from centralized, hospital-based collection to decentralized, accessible, and patient-friendly methods — paving the way for global healthcare equity and early-onset detection.
The Problem
Access to diagnostic information is a fundament of modern healthcare. Yet, traditional blood sampling methods – such as venipuncture – are invasive, costly, and reliant on trained professionals and complex logistics, including biohazard handling and cold-chains.
These challenges make routine testing and large-scale health monitoring highly impractical, particularly in remote, underserved, or resource-limited regions.
An estimated 1/3 of the global population suffer from one or more preventable chronic diseases, underscoring the urgent need for more effective disease management.
Additionally, emerging fields like precision medicine and bioinformatics-driven health insights require scalable and reliable sampling solutions to unlock their full potential. This also affects clinical trials, where 80% are delayed due to difficulty in participant recruitment and low compliance.
Addressing these limitations is critical and requires a shift from centralized, hospital-based collection to decentralized, accessible, and patient-friendly methods — paving the way for global healthcare equity and early-onset detection.
47 T$
Estimated global cost burden for chronic diseases between 2010-2030. 1
80%
OF CLINICAL STUDIES
ARE DELAYED
The Problem
Access to diagnostic information is a fundament of modern healthcare. Yet, traditional blood sampling methods – such as venipuncture – are invasive, costly, and reliant on trained professionals and complex logistics, including biohazard handling and cold-chains.
These challenges make routine testing and large-scale health monitoring highly impractical, particularly in remote, underserved, or resource-limited regions.
An estimated 1/3 of the global population suffer from one or more preventable chronic diseases, underscoring the urgent need for more effective disease management.
Additionally, emerging fields like precision medicine and bioinformatics-driven health insights require scalable and reliable sampling solutions to unlock their full potential. This also affects clinical trials, where 80% are delayed due to difficulty in participant recruitment and low compliance.
Addressing these limitations is critical and requires a shift from centralized, hospital-based collection to decentralized, accessible, and patient-friendly methods — paving the way for global healthcare equity and early-onset detection.
The Solution
Point-of-care SamplingSelf-sampling to meet the demand for scaleable, accessible diagnostics – Requiring no healthcare professionals, cold-chain or bio-hazard logistics!
The Benefits
Our innovative devices enable easy sample collection through a self-administered, user-friendly sampling of Blood and Dermal Interstitial Fluid in the comfort of your own home, eliminating traditional barriers to accessibility.
The samples collected from both devices can be sent by regular post to a laboratory for analysis using DBS assays.
Painless and Easy-to-Use:
Self-administered, one-step, direct-collect sampling.
No Biohazard or Cold-Chain Logistics:
Samples are securely stored in a dry matrix, allowing stable and simple transport via regular post.
High Precision and Reliability:
Collects precise Blood and ISF micro-volumes, compatible with standard DBS analysis.
Enabling Large-Scale or Longitudinal Testing:
Low-cost, all-in-one device that can be re-sterilized or disposed of for recycling, making it ideal for widespread use.
The Benefits
Eliminating accessibility barriersOur innovative devices drastically improves accessibility to health-information through sampling of Blood and Dermal Interstitial Fluid in the comfort of your own home. The samples collected from both devices can be sent by regular post to a laboratory for analysis using DBS assays.
Painless and Easy-to-Use:
Self-administered, one-step, direct-collection sampling.
Precision and Reliability:
Collects precise Blood and ISF micro-volumes, compatible with standard DBS analysis.
Enabling Large-Scale or Longitudinal Testing:
Low-cost, all-in-one device that can be re-sterilized or disposed of for recycling, making it ideal for widespread use.
No Biohazard or Cold-Chain Logistics:
Samples are securely stored in a dry matrix, allowing stable and simple transportation via regular post.
The Solution
Point-of-care SamplingSelf-sampling to meet the demand for scaleable, accessible diagnostics – Requiring no healthcare professionals, cold-chain or bio-hazard logistics!
A micro-solution to a macro-problem – Samplimy is shaping the future of microsampling!
Our innovative devices enable seamless sample collection through a self-administered, easy-to-use sampling of Blood and Dermal Interstitial Fluid in the comfort of your own home, eliminating traditional barriers to accessibility.
The samples collected from both devices can be sent by regular post to a laboratory for analysis using standard DBS assays. Samplimy provides the future of microsampling!
Easy self-administered and cost-effective devices for Blood and Dermal Interstitial Fluid. The samples collected from both devices can be sent by regular post to a laboratory for analysis using standard DBS assays.
The Benefits
Eliminating accessibility barriers
Our innovative devices drastically improves accessibility to health-information through sampling of Blood and Dermal Interstitial Fluid in the comfort of your own home.
The samples collected from both devices can be sent by regular post to a laboratory for analysis using DBS assays.
Painless and Easy-to-Use:
Self-administered, one-step, direct-collection sampling.
Precision and Reliability:
Collects precise Blood and ISF micro-volumes, compatible with standard DBS analysis.
Enabling Large-Scale or Longitudinal Testing:
Low-cost, all-in-one device that can be re-sterilized or disposed of for recycling, making it ideal for widespread use.
No Biohazard or Cold-Chain Logistics:
Samples are securely stored in a dry matrix, allowing stable and simple transportation via regular post.
The Solution
Point-of-care SamplingSelf-sampling to meet the demand for scaleable, accessible diagnostics – Requiring no healthcare professionals, cold-chain or bio-hazard logistics!
The Benefits
Eliminating accessibility barriers
Our innovative devices drastically improves accessibility to health-information through sampling of Blood and Dermal Interstitial Fluid in the comfort of your own home.
The samples collected from both devices can be sent by regular post to a laboratory for analysis using DBS assays.
Painless and Easy-to-Use:
Self-administered, one-step, direct-collection sampling.
Precision and Reliability:
Collects precise Blood and ISF micro-volumes, compatible with standard DBS analysis.
Enabling Large-Scale or Longitudinal Testing:
Low-cost, all-in-one device that can be re-sterilized or disposed of for recycling, making it ideal for widespread use.
No Biohazard or Cold-Chain Logistics:
Samples are securely stored in a dry matrix, allowing stable and simple transportation via regular post.
FEDERICO RIBET - CTO AND CO-FOUNDER
A quick introduction
to our technology
Hear our co-inventor Federico Ribet explain the reason behind the development of our microsampling technology and the benefits that it can provide to the market and end-users.
INNOVATION
Our proprietary product technology is a result of +5 years of research by our world-leading team in microsampling at the Swedish Royal Institute of Technology (KTH).
pARTNERSHIPS
Strategic partnerships is the foundation of our business model, together we can unlock the full potential of your bio-information needs.
First Customers
We currently focus on providing research customers with a robust, user-friendly and price-competitive microsampling platform for collecting body fluids from the skin.
INNOVATION
Our proprietary product technology is a result of +5 years of research by our world-leading team in microsampling at the Swedish Royal Institute of Technology (KTH).
pARTNERSHIPS
Strategic partnerships is the foundation of our business model, together we can unlock the full potential of your bio-information needs.
First Customers
We currently focus on providing research customers with a robust, user-friendly and price-competitive microsampling platform for collecting body fluids from the skin.
partners & investors
Want to know more about
Partnerhip or investment opportunities
– let's get in touch!
